Perillo A, Pierelli L, Scambia G, Leone G, Mancuso S
Department of Gynecology and Obstetrics, Catholic University of the Sacred Heart, Rome, Italy.
Panminerva Med. 2002 Sep;44(3):197-204.
In recent years hematopoietic stem cells (HSC) have been the object of new research efforts and scientific advances. Therapeutic strategies have been set up using HSC for the treatment of solid tumors such as ovarian cancer. In this context different approaches have been proposed and clinically investigated. The "autologous" approach refers to the use of HSC as hematologic support to high-dose chemotherapy regimens, and to the use of HSC as an abundant source of dendritic cells for cancer vaccination protocols. Our institution has developed a long-term experience in high-dose chemotherapy with autologous HSC transplantation as first-line treatment of advanced ovarian cancer, and in the use of cytokines both for the HSC collection and for the post-transplantation hematopoietic recovery. Moreover, the "allogeneic" approach with HSC consists of the allogeneic transplantation with both myeloablative/standard or nonmyeloablative/reduced conditioning regimens, which has been proposed as a new adoptive immunotherapeutic treatment for different nonhematologic malignancies. Perspectives in the use of HSC in oncology comprise the possibility of an HSC ex vivo expansion, the use of umbilical cord blood HSC, and the development of future HSC-based gene-therapy programs.
近年来，造血干细胞（HSC）一直是新的研究工作和科学进展的对象。已经制定了使用造血干细胞治疗实体瘤如卵巢癌的治疗策略。在这种背景下，已经提出并进行了临床研究不同的方法。“自体”方法是指将造血干细胞用作高剂量化疗方案的血液学支持，以及将造血干细胞用作癌症疫苗接种方案中丰富的树突状细胞来源。我们机构在以自体造血干细胞移植作为晚期卵巢癌的一线治疗进行高剂量化疗，以及在使用细胞因子进行造血干细胞采集和移植后造血恢复方面积累了长期经验。此外，造血干细胞的“异体”方法包括采用清髓性/标准或非清髓性/降低强度预处理方案的异体移植，这已被提议作为针对不同非血液系统恶性肿瘤的一种新的过继免疫治疗方法。肿瘤学中使用造血干细胞的前景包括造血干细胞体外扩增的可能性、脐带血造血干细胞的使用以及未来基于造血干细胞的基因治疗方案的开发。
